A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 A5142是一项III期、随机、三组、开放标签研究，比较了以下方案用于HIV感染初始治疗的有效性： - 非核苷类逆转录酶抑制剂（（NNRTI）为基础的方案（依法韦仑[EFV]+司他夫定缓释剂[d4 T XR]（或齐杜伏定[ZDV]+拉米夫定[3 TC]）） - 利托那韦（RTV）-增强蛋白酶抑制剂（PI）为基础的方案（洛匹那韦/利托那韦[LPV/r]+ d4 T XR（或ZDV）+3 TC） - 核苷类逆转录酶抑制剂保留方案（EFV + lPV/r）

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5142 is a Phase III, randomized, three arm, open-label study comparing the effectiveness of the following regimens for the initial treatment of HIV infection: - Nonnucleoside reverse transcriptase inhibitor ((NNRTI)-based regimen (efavirenz [EFV] plus stavudine extended release [d4T XR] (or ziduvodine [ZDV] plus lamivudine [3TC]) - Ritonavir (RTV)-enhanced protease inhibitor (PI)- based regimen (Lopinavir/Ritonavir [LPV/r] plus d4T XR (or ZDV) plus 3TC) - Nucleoside reverse transcriptase inhibitor NRTI)-sparing regimen (EFV plus lPV/r)